The US administration is set to announce that all states will see MFN pricing for certain drugs in Medicaid programmes, Semafor reports citing plans shared

Most-favoured-nation drug pricing has been attempted in prior US administrations, and the pattern is established: executive-branch efforts of this kind have repeatedly run into legal challenge and injunction on procedural and statutory grounds, with the pharmaceutical industry's litigation response a reliable first follow-on. Medicaid is a narrower channel than Medicare or the commercial market, so the direct revenue exposure concentrates in drugs with heavy state-programme utilisation rather than across the sector, and the read-across to the large-cap pharma peer set has historically differentiated on portfolio mix rather than moving the group as one. The distinction that matters is between an announcement, a rule, and a surviving rule: headline-stage pricing initiatives have tended to compress multiples on the most exposed names first, with the durable effect determined by the rulemaking track and court process that follows. The questions are scope, the reference basket of countries, and whether the mechanism is mandatory or negotiated, since prior episodes have been diluted substantially between announcement and implementation. Watch for industry body and manufacturer responses, and for whether the measure is framed as an extension of existing negotiation authorities or a standalone order. As a report of plans rather than a published rule, the signal is directional at this stage.